OCUGEN, INC. (OCGN) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2026-Q1: Total return Win; Revenue growth Lose; EPS growth No data.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth No data.
- 2025-Q3: Total return Win; Revenue growth Win; EPS growth No data.
22/58
1.9 / 5 stars
All 58 Win/Lose results and 62 gray no-data contests shown below
Every strict quarterly win earns 1 point. A loss or tie earns 0. A contest with no data is a gray cell, neither a win nor a loss, and leaves the total: stars are 5 × points won ÷ contests with data.
Trailing 1 year (4 quarters): 3 wins, 5 losses, 4 no dataLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/2 |
LoseOCGN / S&P -15.47% / 15.20% |
LoseOCGN / S&P -3.66% / 15.00% |
No dataOCGN / S&P / 50.40% |
| 2026-Q11/2 |
WinOCGN / S&P 34.07% / -4.33% |
LoseOCGN / S&P -1.26% / 11.30% |
No dataOCGN / S&P / 27.70% |
| 2025-Q40/2 |
LoseOCGN / S&P -17.18% / 2.65% |
LoseOCGN / S&P 8.83% / 9.00% |
No dataOCGN / S&P / 13.40% |
| 2025-Q32/2 |
WinOCGN / S&P 68.04% / 8.12% |
WinOCGN / S&P 14.26% / 4.61% |
No dataOCGN / S&P / 13.45% |
| 2025-Q21/2 |
WinOCGN / S&P 37.39% / 10.94% |
LoseOCGN / S&P -34.54% / 4.83% |
No dataOCGN / S&P / 10.63% |
| 2025-Q10/2 |
LoseOCGN / S&P -12.30% / -4.27% |
LoseOCGN / S&P -31.56% / 4.98% |
No dataOCGN / S&P / 10.57% |
| 2024-Q40/2 |
LoseOCGN / S&P -18.85% / 2.41% |
LoseOCGN / S&P -32.82% / 5.25% |
No dataOCGN / S&P / 6.15% |
| 2024-Q30/2 |
LoseOCGN / S&P -36.00% / 5.89% |
LoseOCGN / S&P -14.64% / 5.89% |
No dataOCGN / S&P / 6.11% |
| 2024-Q20/2 |
LoseOCGN / S&P -5.49% / 4.28% |
No dataOCGN / S&P / 5.38% |
LoseOCGN / S&P -50.00% / 5.12% |
| 2024-Q11/2 |
WinOCGN / S&P 185.22% / 10.56% |
No dataOCGN / S&P / 5.71% |
LoseOCGN / S&P -32.43% / 5.59% |
| 2023-Q41/2 |
WinOCGN / S&P 43.75% / 11.69% |
No dataOCGN / S&P / 6.81% |
LoseOCGN / S&P -26.32% / 7.78% |
| 2023-Q31/2 |
LoseOCGN / S&P -26.34% / -3.27% |
No dataOCGN / S&P / 7.52% |
WinOCGN / S&P -2.86% / -5.03% |
| 2023-Q21/2 |
LoseOCGN / S&P -36.34% / 8.74% |
No dataOCGN / S&P / 9.50% |
WinOCGN / S&P 26.67% / -8.57% |
| 2023-Q11/2 |
LoseOCGN / S&P -34.38% / 7.50% |
No dataOCGN / S&P / 10.77% |
WinOCGN / S&P 8.82% / -15.69% |
| 2022-Q41/2 |
LoseOCGN / S&P -26.97% / 7.56% |
No dataOCGN / S&P / 11.88% |
WinOCGN / S&P 31.03% / -17.99% |
| 2022-Q31/2 |
LoseOCGN / S&P -21.59% / -4.88% |
No dataOCGN / S&P / 13.47% |
WinOCGN / S&P 75.00% / -1.41% |
| 2022-Q21/2 |
LoseOCGN / S&P -31.21% / -16.10% |
No dataOCGN / S&P / 13.71% |
WinOCGN / S&P 36.36% / 11.04% |
| 2022-Q10/2 |
LoseOCGN / S&P -27.47% / -4.60% |
No dataOCGN / S&P / 15.97% |
LoseOCGN / S&P 21.43% / 42.23% |
| 2021-Q40/1 |
LoseOCGN / S&P -36.63% / 11.03% |
No dataOCGN / S&P / 15.00% |
No dataOCGN / S&P / 96.40% |
| 2021-Q30/1 |
LoseOCGN / S&P -10.59% / 0.58% |
No dataOCGN / S&P / 10.77% |
No dataOCGN / S&P / 69.42% |
| 2021-Q21/1 |
WinOCGN / S&P 18.26% / 8.55% |
No dataOCGN / S&P / 6.58% |
No dataOCGN / S&P / 51.81% |
| 2021-Q11/1 |
WinOCGN / S&P 271.04% / 6.17% |
No dataOCGN / S&P / -1.06% |
No dataOCGN / S&P / 7.39% |
| 2020-Q41/1 |
WinOCGN / S&P 490.32% / 12.15% |
No dataOCGN / S&P / -3.72% |
No dataOCGN / S&P / -33.42% |
| 2020-Q31/1 |
WinOCGN / S&P 40.91% / 8.93% |
No dataOCGN / S&P / -2.04% |
No dataOCGN / S&P / -27.10% |
| 2020-Q20/1 |
LoseOCGN / S&P -21.71% / 20.54% |
No dataOCGN / S&P / -0.46% |
No dataOCGN / S&P / -27.11% |
| 2020-Q10/1 |
LoseOCGN / S&P -45.96% / -19.60% |
No dataOCGN / S&P / 3.47% |
No dataOCGN / S&P / -14.75% |
| 2019-Q40/1 |
LoseOCGN / S&P -81.75% / 9.07% |
No dataOCGN / S&P / 5.36% |
No dataOCGN / S&P / 2.99% |
| 2019-Q30/1 |
LoseOCGN / S&P -75.13% / 1.70% |
No dataOCGN / S&P / 5.02% |
No dataOCGN / S&P / 0.21% |
| 2019-Q21/1 |
WinOCGN / S&P 64.66% / 4.30% |
No dataOCGN / S&P / 6.64% |
No dataOCGN / S&P / 8.65% |
| 2019-Q11/1 |
WinOCGN / S&P 31.82% / 13.65% |
No dataOCGN / S&P / 8.12% |
No dataOCGN / S&P / 14.29% |
| 2018-Q40/1 |
LoseOCGN / S&P -83.85% / -13.52% |
No dataOCGN / S&P / 9.05% |
No dataOCGN / S&P / 18.23% |
| 2018-Q30/1 |
LoseOCGN / S&P -78.20% / 7.71% |
No dataOCGN / S&P / 10.21% |
No dataOCGN / S&P / 19.06% |
| 2018-Q20/1 |
LoseOCGN / S&P -9.09% / 3.43% |
No dataOCGN / S&P / 9.03% |
No dataOCGN / S&P / 14.46% |
| 2018-Q11/1 |
WinOCGN / S&P 34.15% / -0.76% |
No dataOCGN / S&P / 7.68% |
No dataOCGN / S&P / 12.46% |
| 2017-Q40/1 |
LoseOCGN / S&P 3.54% / 6.64% |
No dataOCGN / S&P / 7.03% |
No dataOCGN / S&P / 13.82% |
| 2017-Q31/1 |
WinOCGN / S&P 10.61% / 4.48% |
No dataOCGN / S&P / 5.68% |
No dataOCGN / S&P / 17.57% |
| 2017-Q21/1 |
WinOCGN / S&P 3.47% / 3.09% |
No dataOCGN / S&P / 4.83% |
No dataOCGN / S&P / 17.74% |
| 2017-Q10/1 |
LoseOCGN / S&P 3.59% / 6.07% |
No dataOCGN / S&P / 3.67% |
No dataOCGN / S&P / 13.32% |
| 2016-Q40/1 |
LoseOCGN / S&P -47.98% / 3.82% |
No dataOCGN / S&P / 2.09% |
No dataOCGN / S&P / 7.05% |
| 2016-Q31/1 |
WinOCGN / S&P 87.72% / 3.85% |
No dataOCGN / S&P / 0.20% |
No dataOCGN / S&P / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | OCGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | 34.31% | 20.78% |
| Annualized return | 34.31% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | OCGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -81.78% | 83.14% |
| Annualized return | -28.86% | 12.86% |
10Y · 2016-09-01 to 2026-08-27
| Metric | OCGN total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -99.29% | 319.30% |
| Annualized return | -39.04% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| FENNEC PHARMACEUTICALS INC. (FENC) | United States | $0.371B | -115.85 |
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B |